Amylyx PharmaceuticalsAMLX +5.41%33 Market Cap is $1,992.46 Mil as of Jun. 25, 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks better than 84.65% on this metric.
Amylyx Pharmaceuticals's quarterly market cap
declined
from Sep. 2025 ($1,491.72 Mil) to Dec. 2025 ($1,327.41 Mil) but then
increased
from Dec. 2025 ($1,327.41 Mil) to Mar. 2026 ($1,543.26 Mil).
Amylyx Pharmaceuticals's annual market cap
declined
from Dec. 2023 ($996.65 Mil) to Dec. 2024 ($259.42 Mil) but then
increased
from Dec. 2024 ($259.42 Mil) to Dec. 2025 ($1,327.41 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amylyx Pharmaceuticals's Enterprise Value for Today is $1,718.32 Mil.
Amylyx Pharmaceuticals (NAS:AMLX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amylyx Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Amylyx Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals (AMLX) has a Market Cap of $1,992.46 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amylyx Pharmaceuticals and its competitors. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #157 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 15.3%.
Is Amylyx Pharmaceuticals' Market Cap too high?
Amylyx Pharmaceuticals' current Market Cap is $1,992.46 Mil. The Drug Manufacturers industry median Market Cap is 206.50. Amylyx Pharmaceuticals' value of $1,992.46 Mil is 864.9% above this industry median. Based on the distribution chart, Amylyx Pharmaceuticals ranks #157 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' Market Cap compare to PRGO and ANIP?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #157 out of 1023 companies for Market Cap. This places Amylyx Pharmaceuticals in the top 15% of its industry — outperforming the majority of peers. The industry median Market Cap is 206.50. Amylyx Pharmaceuticals' value of $1,992.46 Mil is 864.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.50, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amylyx Pharmaceuticals's current Market Cap of $1,992.46 Mil is 864.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amylyx Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amylyx Pharmaceuticals's current Market Cap is $1,992.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current Market Cap of $1,992.46 Mil. The current Market Cap is $1,992.46 Mil and 864.9% above the Drug Manufacturers industry median of 206.50. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current Market Cap is $1,992.46 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score
Get the complete analysis for AMLX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMLX has been successfully added to your 
